Compare Bristol-Myers Squibb Co (BMY) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nike Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Nike Inc trades at $43.31 (market cap $63.47B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NKE | |
|---|---|---|
Market Cap | $116.30B | $63.47B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $79.24 |
52-Week Low | $42.60 | $40.75 |
Enterprise Value | $152.24B | $65.48B |
Dividend Yield | 4.42% | 3.83% |
Volume | — | 8,887,180 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Nike (NKE) trades at $43.76, down 1.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $46.31B for 2025 with a net income margin of 6.7%, though earnings have beaten expectations in recent quarters. Analysts maintain a consensus buy rating with a $50.80 price target, suggesting potential upside from current levels.
Nike's outlook is supported by strong brand equity and consistent earnings beats, but faces headwinds from softer demand in China and margin pressure. The stock presents a value opportunity with a P/E of 20.41 below historical averages, though execution risks in the turnaround strategy remain key for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
